Edwards Lifesciences (NYSE:EW – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share guidance of 2.700-2.800 for the period, compared to the consensus earnings per share estimate of 2.750. The company issued revenue guidance of $6.6 billion-$6.6 billion, compared to the consensus revenue estimate of $6.5 billion. Edwards Lifesciences also updated its FY24 guidance to $2.70-2.80 EPS.
Edwards Lifesciences Trading Down 0.7 %
NYSE EW traded down $0.60 during trading on Thursday, hitting $88.01. The company had a trading volume of 4,166,251 shares, compared to its average volume of 3,829,875. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. Edwards Lifesciences has a one year low of $60.57 and a one year high of $96.12. The company has a market cap of $52.98 billion, a price-to-earnings ratio of 38.53, a price-to-earnings-growth ratio of 4.35 and a beta of 1.05. The company’s fifty day moving average is $90.23 and its 200-day moving average is $78.69.
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, meeting the consensus estimate of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same period in the prior year, the firm posted $0.64 EPS. Edwards Lifesciences’s revenue for the quarter was up 13.3% on a year-over-year basis. On average, sell-side analysts predict that Edwards Lifesciences will post 2.76 earnings per share for the current year.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on Edwards Lifesciences
Insider Buying and Selling at Edwards Lifesciences
In other news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 11,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total value of $944,130.00. Following the sale, the vice president now owns 39,503 shares of the company’s stock, valued at approximately $3,390,542.49. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 194,004 shares of company stock worth $17,166,254. Corporate insiders own 1.29% of the company’s stock.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Featured Articles
- Five stocks we like better than Edwards Lifesciences
- NYSE Stocks Give Investors a Variety of Quality Options
- Hasbro’s Management Made All the Right Calls This Quarter
- How to Start Investing in Real Estate
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- What Are Dividend Champions? How to Invest in the Champions
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.